Revolutionizing Retinal Therapy: The Role of Nanoparticle Drug Carriers in Managing Vascular Retinal Disorders.

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.2147/OPTH.S503273
Huihui Lu, Na He, Lina Zhang, Yayan You, Zhigang Lv
{"title":"Revolutionizing Retinal Therapy: The Role of Nanoparticle Drug Carriers in Managing Vascular Retinal Disorders.","authors":"Huihui Lu, Na He, Lina Zhang, Yayan You, Zhigang Lv","doi":"10.2147/OPTH.S503273","DOIUrl":null,"url":null,"abstract":"<p><p>Vascular Retinopathy (VR), such as diabetic retinopathy, pose significant challenges to vision and overall health. Traditional treatment methods often face limitations in efficacy and delivery. Vascular retinopathy is a common and potentially blinding group of eye diseases with core pathologic mechanisms involving vascular injury, ischemia, exudation, and neovascularization. Clinical management relies heavily on etiologic control (eg, diabetes, hypertension), anti-VEGF therapy, laser therapy, and surgical intervention. Recent advancements in nanotechnology have led to the development of innovative nanoparticle drug carriers, which offer promising solutions for targeted and sustained drug delivery in the retinal environment. This review explores the application of both conventional and novel nanoparticle carriers in treating VR. We discuss various types of nanoparticles, including liposomes, polymeric nanoparticles, and metal-based carriers, highlighting their unique properties, mechanisms of action, and therapeutic benefits. Finally, we provide insights into future perspectives for nanoparticle-based therapies in retinal disorders, emphasizing the potential for improved patient outcomes and the need for further research to optimize these advanced drug delivery systems.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"1565-1582"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087915/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S503273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Vascular Retinopathy (VR), such as diabetic retinopathy, pose significant challenges to vision and overall health. Traditional treatment methods often face limitations in efficacy and delivery. Vascular retinopathy is a common and potentially blinding group of eye diseases with core pathologic mechanisms involving vascular injury, ischemia, exudation, and neovascularization. Clinical management relies heavily on etiologic control (eg, diabetes, hypertension), anti-VEGF therapy, laser therapy, and surgical intervention. Recent advancements in nanotechnology have led to the development of innovative nanoparticle drug carriers, which offer promising solutions for targeted and sustained drug delivery in the retinal environment. This review explores the application of both conventional and novel nanoparticle carriers in treating VR. We discuss various types of nanoparticles, including liposomes, polymeric nanoparticles, and metal-based carriers, highlighting their unique properties, mechanisms of action, and therapeutic benefits. Finally, we provide insights into future perspectives for nanoparticle-based therapies in retinal disorders, emphasizing the potential for improved patient outcomes and the need for further research to optimize these advanced drug delivery systems.

革命性的视网膜治疗:纳米颗粒药物载体在管理血管性视网膜疾病中的作用。
血管性视网膜病变(VR),如糖尿病视网膜病变,对视力和整体健康构成重大挑战。传统的治疗方法往往面临疗效和递送的限制。血管性视网膜病变是一种常见且可能致盲的眼病,其核心病理机制涉及血管损伤、缺血、渗出和新生血管。临床管理很大程度上依赖于病因控制(如糖尿病、高血压)、抗vegf治疗、激光治疗和手术干预。纳米技术的最新进展导致了创新纳米颗粒药物载体的发展,这为视网膜环境中靶向和持续的药物递送提供了有希望的解决方案。本文综述了传统纳米粒子载体和新型纳米粒子载体在VR治疗中的应用。我们讨论了各种类型的纳米颗粒,包括脂质体、聚合物纳米颗粒和金属基载体,强调了它们独特的性质、作用机制和治疗效益。最后,我们对基于纳米颗粒的视网膜疾病治疗的未来前景提供了见解,强调了改善患者预后的潜力以及进一步研究优化这些先进药物输送系统的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信